Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernando Bessone

Showing results (31-40 of 72) with videos related to

Pageof 8
Sort By:
Annals of Hepatology|February 20, 2021
Drug-induced liver injury: A management position paper from the Latin American Association for Study of the liverFernando Bessone, Nelia Hernandez, Martin Tagle, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 9, 2018
The influence of drug properties and host factors on delayed onset of symptoms in drug-induced liver injuryAndres Gonzalez-Jimenez, Kristin McEuen, Minjun Chen, et al.
Annals of Hepatology|February 21, 2014
Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reportsNelia Hernández, Fernando Bessone, Adriana Sánchez, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 10, 2011
Trends and projections of hepatitis C virus epidemiology in Latin AmericaDavid Kershenobich, Homie A Razavi, Juan Francisco Sánchez-Avila, et al.
Drugs in Context|July 13, 2016
Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: results from the 2-year roadmap strategyTeerha Piratvisuth, Piyawat Komolmit, Henry Ly Chan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 15, 2010
Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis BEugene R Schiff, Samuel S Lee, You-Chen Chao, et al.
Plos One|February 8, 2013
52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis BTeerha Piratvisuth, Piyawat Komolmit, Tawesak Tanwandee, et al.
Journal of Clinical and Experimental Hepatology|March 5, 2025
Stanozolol-induced Liver Injury: A Distinctive Cholestatic Clinical and Biochemical Phenotype at PresentationVinícius Nunes, Maria I Schinoni, Fernando Bessone, et al.
World Journal of Hepatology|April 14, 2015
Pre-treatment prediction of response to peginterferon plus ribavirin in chronic hepatitis C genotype 3Sebastián Marciano, Silvia M Borzi, Melisa Dirchwolf, et al.
Hepatology (Baltimore, Md.)|January 30, 2013
Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trialMark S Sulkowski, Tarik Asselah, Jacob Lalezari, et al.
Pageof 8

Showing results (31-40 of 72) with videos related to

Sort By:
Pageof 8
Annals of Hepatology|February 20, 2021
Drug-induced liver injury: A management position paper from the Latin American Association for Study of the liverFernando Bessone, Nelia Hernandez, Martin Tagle, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 9, 2018
The influence of drug properties and host factors on delayed onset of symptoms in drug-induced liver injuryAndres Gonzalez-Jimenez, Kristin McEuen, Minjun Chen, et al.
Annals of Hepatology|February 21, 2014
Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reportsNelia Hernández, Fernando Bessone, Adriana Sánchez, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 10, 2011
Trends and projections of hepatitis C virus epidemiology in Latin AmericaDavid Kershenobich, Homie A Razavi, Juan Francisco Sánchez-Avila, et al.
Drugs in Context|July 13, 2016
Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: results from the 2-year roadmap strategyTeerha Piratvisuth, Piyawat Komolmit, Henry Ly Chan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 15, 2010
Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis BEugene R Schiff, Samuel S Lee, You-Chen Chao, et al.
Plos One|February 8, 2013
52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis BTeerha Piratvisuth, Piyawat Komolmit, Tawesak Tanwandee, et al.
Journal of Clinical and Experimental Hepatology|March 5, 2025
Stanozolol-induced Liver Injury: A Distinctive Cholestatic Clinical and Biochemical Phenotype at PresentationVinícius Nunes, Maria I Schinoni, Fernando Bessone, et al.
World Journal of Hepatology|April 14, 2015
Pre-treatment prediction of response to peginterferon plus ribavirin in chronic hepatitis C genotype 3Sebastián Marciano, Silvia M Borzi, Melisa Dirchwolf, et al.
Hepatology (Baltimore, Md.)|January 30, 2013
Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trialMark S Sulkowski, Tarik Asselah, Jacob Lalezari, et al.
Pageof 8